Alexander Stoeckel

Based in Diepenbeek, Belgium, Softhale N.V. is a pharmaceutical company specializing in the development of inhalable respiratory products for the medical treatment of various indications including, for example, Asthma or COPD. In Softhale’s office and labs, the focus lies on product development, formulation development, and analytical capabilities. The team is led by international industry experts (hardware, formulation, analytics, manufacturing, commercialization) and supported by external (inter-)national services providers. The Company’s proprietary, propellant-free, purely mechanical device delivers medication to the lungs more effectively than other types of inhalers and is poised to change the treatment paradigm in large markets including asthma and COPD. Softhale’s products to be used for pharmaceutical development and approval processes are innovative as well as cost-optimized. Softhale is ISO 13485: 2016 certified.

Backing the Unique, the Mavericks, the Outliers b2venture is a European venture firm, leveraging the power of generations to shape tomorrow. We invest at the earliest stages in the best ideas and the brightest minds so they can take flight.

Based in Diepenbeek, Belgium, Softhale N.V. is a pharmaceutical company specializing in the development of inhalable respiratory products for the medical treatment of various indications including, for example, Asthma or COPD. In Softhale’s office and labs, the focus lies on product development, formulation development, and analytical capabilities. The team is led by international industry experts (hardware, formulation, analytics, manufacturing, commercialization) and supported by external (inter-)national services providers. The Company’s proprietary, propellant-free, purely mechanical device delivers medication to the lungs more effectively than other types of inhalers and is poised to change the treatment paradigm in large markets including asthma and COPD. Softhale’s products to be used for pharmaceutical development and approval processes are innovative as well as cost-optimized. Softhale is ISO 13485: 2016 certified.

PM Equity Partner is the corporate venture capital arm of Philip Morris International (PMI) (NYSE:PM). We actively seek investment opportunities in innovative technologies and business that support PMIs vision toward a smoke-free future and in new areas in the wellness and healthcare space, as well as social and environmental impact investments. Our long-term investment approach offers the stability for achieving remarkable and sustainable results. We collaborate to innovate, explore, leverage knowledge and share perspectives together.

Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. In November 2022, PMI acquired Swedish Match – a leader in oral nicotine delivery – creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. As of September 30, 2023, PMIs smoke-free products were available for sale in 82 markets, and PMI estimates that approximately 19.7 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products account for approximately 36.2% of PMI’s total third-quarter 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com. Our priority is to attract, support and keep with us diverse and unique individuals. Our global workforce of more than 69,000 people is one of our greatest strengths and the key to our success as a company. Our employees speak more than 80 languages and come from all corners of the world. PMI has also been certified as a “Global Top Employer” for the seventh consecutive year, in recognition of the high standards of excellence in our working environment and the exceptional development opportunities we offer. If you come into our offices or meet our people, you will quickly realize that at PMI everyone has the opportunity to make a difference and build phenomenal careers.

The Swiss Private Equity & Corporate Finance Association (SECA) is the representative body for Switzerland‘s private equity, venture capital and corporate finance industries. SECA has the objective to promote private equity and corporate finance activities in Switzerland. Members of the SECA include equity investment companies, banks, corporate finance advisors, auditing companies, management consultants, lawyers and private investors. Learn more about SECA or visit one of our five chapters "Innovation & VC"​, "Private Equity"​, "Legal & Tax"​, "Corporate Finance"​ and "Communication and Media"​.

Backing the Unique, the Mavericks, the Outliers b2venture is a European venture firm, leveraging the power of generations to shape tomorrow. We invest at the earliest stages in the best ideas and the brightest minds so they can take flight.